Donafenib
Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.
Overview
Zelgen's donafenib was approved by the NMPA in June 2021 for first-line unresectable hepatocellular carcinoma on the ZGDH3 trial (668 patients: median overall survival 12.1 versus 10.3 months with sorafenib, hazard ratio 0.83; Journal of Clinical Oncology 2021), the first drug to beat sorafenib on survival in this setting. Radioiodine-refractory differentiated thyroid cancer followed in 2022. A modest gain, but a first for a Chinese company and a model of incremental chemistry (deuteration) turned into an approval.
1.Donafenib slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2021 | First-line unresectable hepatocellular carcinoma (ZGDH3) |
| China | 2022 | Radioiodine-refractory differentiated thyroid cancer |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Donafenib" OR ABSTRACT:"Donafenib" OR TITLE:"Zepsun" OR ABSTRACT:"Zepsun" OR TITLE:"CM4307" OR ABSTRACT:"CM4307") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Donafenib, not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentSorafenib
Shares Thyroid cancer, Hepatocellular carcinoma.
- CompanyEli Lilly (incl. Loxo)
Shares Thyroid cancer, Hepatocellular carcinoma.
- CompanyBayer
Shares Thyroid cancer, Hepatocellular carcinoma.
- InstitutionMemorial Sloan Kettering Cancer Center
Shares Thyroid cancer, Hepatocellular carcinoma.
- AgentCabozantinib
Shares Thyroid cancer, Hepatocellular carcinoma.
- AgentPembrolizumab
Shares Thyroid cancer, Hepatocellular carcinoma.
- CompanyAstraZeneca
Shares Thyroid cancer, Hepatocellular carcinoma.